Nutex Health Overview
Latest ROE for Nutex Health: 35.46% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow35.46%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Nutex Health posts a ROE of 35.46%. That is below the Consumer Staples sector average of 75.63%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Consumer Staples stocks, a ROE near 75.63% is typical. Nutex Health's 35.46% is lower that level. That is roughly 53.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Nutex Health's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 35.46%; use YoY and peer views to separate noise from signal.
Context for NUTX's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 75.63%), and (3) consistency with growth and profitability. This page covers the first two; Nutex Health's other metric pages and overview cover the third.
Judging Nutex Health against Consumer Staples peers is usually better than using a market-wide rule of thumb. Business models inside Consumer Staples are more comparable, which makes gaps in ROE easier to interpret. Start with 35.46% here, then scan peer and history charts to see if the gap is persistent.
